Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Watch Dopesick on Disney Plus
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jan 05, 2023 5:03pm
307 Views
Post# 35205632

RE:RE:RE:RE:RE:Watch Dopesick on Disney Plus

RE:RE:RE:RE:RE:Watch Dopesick on Disney PlusYes Bagger.

Now think about the patents for a moment.
We knew there was going to be opportunity to get the IP to 20 years.
But there's much more to the IP game.

It's the gift that keeps on giving ...

1.  The initial layer of IP is the "composition of matter" patent.

2.  The next layer on top of that is "regime" related.  There will be one regime for acute (consisting of load/maintenance/taper doses) but you will eventually see a specific regime for the chronic side (sophisticated regime).  If we're luck, there might even be a different regime for pre-op and a different regime for intra-op.  You just never know what comes out of this.

3.  The next layer of IP includes the formulation.  For OTENA, we have the modified formulation from crystalline to amorphous.

The web of patents is making it tougher and tougher to mess with us and that's exactly what we want to see - IMO.

I don't think it ends there - there are opportunities for more layers down the road !  Amen !
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities